ASCO Report 2015: Immunotherapy nivolumab improves survival in squamous-non-small cell lung cancer
by Bruce Sylvester: In a Phase III trial comparing standard docetaxel chemotherapy with immunotherapy nivolumab, researchers reported that subjects with squamous-non-small cell lung cancer treated with nivolumab lived… read more.